Skip to main content
. 2023 Oct 12;6(10):e2337348. doi: 10.1001/jamanetworkopen.2023.37348

Table 1. Characteristics of the Included RCTs and Cohort Studies.

Source Country Cancer type Biosimilar drug Reference drug Patients, No. a Females, No./males, No. Primary end point Study design
Bevacizumab biosimilar vs bevacizumab
Stroyakovskiy et al,34 2022 Russia NSCLC BCD-021 Bevacizumab 357 110/230 ORR RCT
Thatcher et al,48 2019 UK NSCLC ABP215 Bevacizumab 642 NA ORR RCT
Reinmuth et al,49 2019 US NSCLC PF-06439535 Bevacizumab 719 252/467 ORR RCT
Reck et al,46 2020 Korea NSCLC SB8 Bevacizumab 763 255/508 ORR RCT
Yang et al,47 2019 China NSCLC IBI305 Bevacizumab 450 162/279 ORR RCT
Trukhin et al,39 2021 Ukraine NSCLC MB02 Bevacizumab 627 244/383 ORR RCT
Rezvani et al,45 2020 Iran MCRC BE1040V Bevacizumab 126 35/91 PFS RCT
Qin et al,43 2021 China MCRC HLX04 Bevacizumab 677 271/404 PFS RCT
Shi et al,42 2021 China NSCLC LY01008 Bevacizumab 649 237/352 ORR RCT
Chu et al,44 2021 China NSCLC QL1101 Bevacizumab 535 217/318 ORR RCT
Hengrui (sponsor),36 2022 China NSCLC BP102 Bevacizumab 517 NA ORR RCT
Wan et al,38 2021 China NSCLC MIL60 Bevacizumab 517 183/325 ORR RCT
Syrigos et al,40 2021 UK NSCLC FKB238 Bevacizumab 731 248/483 ORR RCT
Kim et al,35 2021 US NSCLC BI695502 Bevacizumab 671 246/417 ORR RCT
Socinski et al,41 2021 US NSCLC MYL-14020 Bevacizumab 671 247/424 ORR RCT
Chen et al,37 2022 China NSCLC BAT1706 Bevacizumab 651 NA ORR RCT
Lu et al,32 2023 China NSCLC Table 008 Bevacizumab 549 194/457 ORR RCT
Verschraegen et al,33 2022 US NSCLC CT-P16 Bevacizumab 689 149/397 ORR RCT
Zhao et al,71 2023 China DLBCL QL1101 Bevacizumab 946 413/533 ORR Cohort study
Rituximab biosimilar vs rituximab
Kaplanov et al,61 2014 Russia FL BCD-020 Rituximab 92 NA ORR RCT
Toogeh et al,57 2018 Iran CLL Zytux Rituximab 70 13/57 ORR RCT
Jurczak et al,60 2017 Poland FL GP2013 Rituximab 629 350/277 ORR RCT
Kim et al,59 2017 Korea FL CT-P10 Rituximab 140 77/63 ORR RCT
Ogura et al,58 2018 Japan FL CT-P10 Rituximab 258 145/123 ORR RCT
Poddubnaya et al,54 2020 Russia Indolent NHL BCD-020 Rituximab 174 90/84 ORR RCT
Candelaria et al,56 2019 Mexico DLBCL RTXM83 Rituximab 272 117/155 ORR RCT
Sharman et al,53 2020 US FL PF-05280586 Rituximab 394 216/178 ORR RCT
Niederwieser et al,55 2020 Germany FL ABP 798 Rituximab 256 126/130 ORR RCT
Archigen (sponsor),51 2020 Korea FL SAIT101 Rituximab 315 174/141 ORR RCT
Shi et al,52 2020 China DLBCL HLX01 Rituximab 407 182/220 ORR RCT
Song et al,50 2021 China DLBCL IBI301 Rituximab 419 202/214 ORR RCT
Roy et al,74 2013 India DLBCL Reditux Rituximab 173 51/112 NA Cohort study
Bankar et al,73 2020 India DLBCL Reditux Rituximab 152 41/111 NA Cohort study
Deng et al,72 2022 China DLBCL HLX-01 Rituximab 33 13/20 NA Cohort study
Trastuzumab biosimilar vs trastuzumab
Stebbing et al,69 2017 UK Early BC CT-P6 Trastuzumab 549 549/0 PCR RCT
Rugo et al,70 2017 US MBC MYL-14010 Trastuzumab 500 500/0 ORR RCT
von Minckwitz et al,67 2018 Germany Early BC ABP 980 Trastuzumab 725 725/0 PCR RCT
Pivot et al,68 2018 France Early BC SB3 Trastuzumab 875 875/0 PCR RCT
Pegram et al,66 2019 US MBC PF-05280014 Trastuzumab 707 707/0 ORR RCT
Pivot et al,62 2022 France Early BC HD201 Trastuzumab 502 502/0 PCR RCT
Alexeev et al,65 2020 Russia MBC BCD-022 Trastuzumab 225 225/0 ORR RCT
Xu et al,64 2021 China MBC HLX02 Trastuzumab 649 649/0 ORR RCT
Nodehi et al,63 2022 Iran Early BC TA4415V Trastuzumab 92 92/0 PCR RCT
Bae et al,80 2021 Korea Early and metastatic BC CT-P6 Trastuzumab 254 NA PCR and PFS Cohort study
Park et al,77 2022 Korea Advanced GC CT-P6 Trastuzumab 102 14/88 NA Cohort study
Yang et al,76 2022 Canada Early BC MYL-1401O Trastuzumab 136 NA PCR Cohort study
Bernat-Peguera et al,79 2022 Spain Early BC CT-P6 Trastuzumab 44 NA NA Cohort study
Eser et al,75 2023 Turkey Early and metastatic BC MYL-1401O Trastuzumab 53 NA PCR and PFS Cohort study
Liu et al,78 2022 China Early BC HLX02 Trastuzumab 105 105/0 NA Cohort study

Abbreviations: BC, breast cancer; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GC, gastric cancer; MBC, metastatic breast cancer; MCRC, metastatic colorectal cancer; NA, not available; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung cancer; ORR, objective response rate; PCR, pathologic complete remission; PFS, progression-free survival; RCT, randomized clinical trial.

a

The number of patients was defined as the number of patients at randomization. The combined number of males and females of some studies does not equal the patient total because data on sex were missing for some patients.